Related Experiment Video

Updated: Aug 8, 2026

Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease
09:34

Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease

Published on: April 4, 2018

Slc11a1 (formerly Nramp1) polymorphisms and susceptibility to post-transplant lymphoproliferative disease following

N R Barshes1, T R Lee, J A Goss

  • 1Michael E. DeBakey Department of Surgery, Baylor College of Medicine, Houston, TX 77030, USA.

Transplant Infectious Disease : an Official Journal of the Transplantation Society
|June 1, 2006
PubMed

Insights

Genetic variations in the solute carrier family 11 member 1 (Slc11a1) gene, specifically 3'-UTR polymorphisms, are linked to post-transplant lymphoproliferative disease (PTLD) risk and Epstein-Barr virus (EBV) titers in pediatric liver transplant recipients.

Area of Science:

  • Immunogenetics
  • Transplantation immunology

Background:

  • Solute carrier family 11 member 1 (Slc11a1) gene polymorphisms are linked to infectious disease, anti-tumor immunity, and autoimmune conditions.
  • Post-transplant lymphoproliferative disease (PTLD) is associated with impaired immune response to Epstein-Barr virus (EBV) in immunosuppressed patients.

Purpose of the Study:

  • To investigate the association between Slc11a1 gene polymorphisms and susceptibility to PTLD in pediatric liver transplant recipients.
  • To determine if Slc11a1 polymorphisms correlate with Epstein-Barr virus (EBV) serum titers post-transplantation.

Main Methods:

  • Whole blood samples from 45 pediatric liver transplant recipients were analyzed.
  • Polymerase chain reaction (PCR) was used to identify D543N and 3 -UTR polymorphisms in the Slc11a1 gene.
  • PTLD status and EBV serum titers were correlated with identified Slc11a1 polymorphisms.

Main Results:

  • Six out of 45 pediatric recipients developed PTLD.
  • A significant association was observed between 3 -UTR polymorphisms of Slc11a1 and PTLD incidence (P = 0.005).
  • Higher post-transplant EBV serum titers were noted in recipients with specific Slc11a1 polymorphisms (P = 0.009).
  • No association was found between the D543N polymorphism and PTLD incidence.

Conclusions:

  • 3 -UTR polymorphisms of the Slc11a1 gene are associated with PTLD susceptibility and EBV immune response in pediatric liver transplant patients.
  • Genotyping for Slc11a1 polymorphisms may aid in identifying high-risk pediatric patients for PTLD and elevated EBV titers.
Abstract

Related Concept Videos

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters01:16

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
Non-LTR Retrotransposons03:18

Non-LTR Retrotransposons

As the name suggests, non-LTR retrotransposons lack the long terminal repeats characteristic of the LTR retrotransposons. Additionally, both LTR and non-LTR retrotransposons use distinct mechanisms of mobilization. Non-LTR retrotransposons are further divided into two classes - Long interspersed nuclear elements (LINEs) and short interspersed nuclear elements (SINEs), both of which occur abundantly in most mammals, including humans. Some of the active non-LTR retrotransposons in humans are L1...
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
Alternative RNA Splicing02:18

Alternative RNA Splicing

Alternative RNA splicing is the regulated splicing of exons and introns to produce different mature mRNAs from a single pre-mRNA. Unlike in constitutive splicing where a single gene produces a single type of mRNA, alternative splicing allows an organism to produce multiple proteins from a single gene and plays an important role in protein diversity.
There are five types of alternative RNA splicing that vary in the ways the pre-mRNA segments are removed or retained in the mature mRNA. The first...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...